Loading…
Loading…
BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Cencora to acquire American Oncology Network in $2.4 billion deal
CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states. “The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “AON serves as a trusted p.
IFP Advisors Inc raised its holdings in Cencora, Inc. (NYSE: COR) by 227.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,264 shares of the company's stock after acquiring an additional 14,078 shares during the quarter. IFP Advisors Inc's holdings
Frank Rimerman Advisors LLC grew its holdings in Cencora, Inc. (NYSE: COR) by 235.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,336 shares of the company's stock after buying an additional 3,043 shares during the quarter. Frank Rimerman
Cencora (NYSE: COR - Get Free Report) and Option Care Health (NASDAQ: OPCH - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Earnings and Valuation This table compares Cencora and
Cencora (COR) stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. COR's operational leverage and AI-enabled efficiency improvements have driven adjusted operating income up 17% YoY, outpacing 4.9% sales growth. Trading at a forward GAAP P/E of 17.7x—about 25% below sector median—COR merits a 12.5% re-rating, targeting $365–$366 per share.